Development of an improved IP1 assay for the characterization of 5-HT2C receptor ligands

Assay and Drug Development Technologies

Volumn 8, Issue 1, 2010, Pages 106-113

  Zhang, Jean Y ^a   Kowal, Dianne M ^a   Nawoschik, Stanley P ^a   Dunlop, John ^a   Pausch, Mark H ^a   Peri, Ravikumar ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; INOSITOL PHOSPHATE; PHOSPHATIDYLINOSITIDE; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CHO CELL; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; HUMAN; HYDROLYSIS; NONHUMAN; RADIOACTIVITY;

ANIMALS; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; INOSITOL PHOSPHATES; LIGANDS; RECEPTOR, SEROTONIN, 5-HT2C;

EID: 77649139317     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0205     Document Type: Article

References (18)

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-996.
2. O'Neill LA: Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 2006;5(7):549-563.
3. Pangalos MN, Schechter LE, Hurko O: Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 2007;6(7):521-532.
4. Nature Reviews Drug Discovery GPCR Questionnaire Participants. The state of GPCR research in 2004. Nat Rev Drug Discov 2004;3(7):575, 577-626.
5. Neubig RR, Siderovski DP: Regulators of G-protein signalling as new central nervous system drug targets. Nat Rev Drug Discov 2002;1(3):187-197.
6. Zhang Y, Kowal D, Kramer A, Dunlop J: Evaluation of FLIPR Calcium 3 Assay Kit-a new no-wash fluorescence calcium indicator reagent. J Biomol Screen 2003;8(5):571-577.
7. Thomsen W, Frazer J, Unett D: Functional assays for screening GPCR targets. Curr Opin Biotechnol 2005;16(6):655-665.
8. Bergsdorf C, Kropp-Goerkis C, Kaehler I, Ketscher L, Boemer U, Parczyk K, et al.: A one-day, dispense-only IP-One HTRF assay for high-throughput screening of Galphaq protein-coupled receptors: towards cells as reagents. Assay Drug Dev Technol 2008;6(1):39-53.
9. Trinquet E, Fink M, Bazin H, Grillet F, Maurin F, Bourrier E, et al.: D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Anal Biochem 2006;358(1):126-135.
10. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 1999;38(8):1083-1152.
11. Baxter G, Kennett G, Blaney F, Blackburn T: 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci 1995;16(3):105-110.
12. Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, et al.: Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res 2006;1073-1074:240-251.
13. Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, et al.: WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1, 4] diazepino[6,7,1h i]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 2005;313(2):862-869.
14. Berridge MJ, Irvine RF: Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984;312(5992):315-321.
15. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 2006;71(4):521-529.
16. Berridge MJ: Inositol trisphosphate and calcium signalling. Nature 1993; 361(6410):315-325.
17. Berridge MJ, Downes CP, Hanley MR: Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982;206(3):587-595.
18. Liu JJ, Hartman DS, Bostwick JR: An immobilized metal ion affinity adsorption and scintillation proximity assay for receptor-stimulated phosphoinositide hydrolysis. Anal Biochem 2003;318(1):91-99.